ORPHA:213721
Undifferentiated carcinoma of the corpus uteri
Also known as: Endometrial undifferentiated carcinoma
Publications
17
29.2th percentile
Trials
17
Interventional, condition-specific
Researchers
140
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Undifferentiated carcinoma of the corpus uteri is a rare cancer of corpus uteri presenting as a large, polypoid, intraluminal mass with necrosis, composed of small to intermediate-size, relatively uniform, dyshesive cells displaying no differentiation. It usually presents with dysfunctional bleeding or vaginal discharge and, less often, abdominal pain. Association with Lynch syndrome was reported.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016267
- UMLS:C4707822
Additional Mondo synonyms (1)
body of uterus undifferentiated carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
17 matched papers (11 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
17 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
17
17 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
17 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
11 in the last 10 years · high confidence · 29.2th percentile (publications denominator)
Phrase hits: 17 · MeSH hits: 0
Who's working on it?
140
Distinct author names in 17 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Fujiwara H2 papers · 2021
Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan.
Papers in Europe PMC - 02Giordano G2 papers · 2023
Department of Medicine and Surgery, Pathology Unit, University of Parma, Viale A. Gramsci, 14, 43126 Parma, Italy.
Papers in Europe PMC - 03Zhang S2 papers · 2026
Department of Gynecology Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Papers in Europe PMC - 04Altrabulsi B1 paper · 2005
Department of Pathology, Baylor University, 1515 Holcombe Boulevard, Dallas, TX 77030, USA.
Papers in Europe PMC - 05
- 06Annunziata CM1 paper · 2026
Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Papers in Europe PMC - 07
- 08Avril S1 paper · 2021
Department of Pathology and the Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA.
Papers in Europe PMC - 09Berretta R1 paper · 2022
Department of Medicine and Surgery, Unit of Surgical Sciences, Obstetrics and Gynecology, University of Parma, Italy.
Papers in Europe PMC - 10Bodurka DC1 paper · 2005Papers in Europe PMC
Clinical research
Is a treatment being tested?
17
interventional trials for this specific condition
17 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 36 trials are registered for undifferentiated carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
17 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 94.4th percentile).
high confidence · 94.4th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
17 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05112601·RECRUITING·Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Not reviewed·Conditions: Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Dedifferentiated Carcinoma · Endometrial Endometrioid Adenocarcinoma·Matched via name phrase
- NCT05256225·RECRUITING·Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Not reviewed·Conditions: Endometrial Carcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Dedifferentiated Carcinoma · Endometrial Endometrioid Adenocarcinoma·Matched via name phrase
Broader category: undifferentiated carcinoma
36
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05925491·RECRUITING·Pembrolizumab in Locally Advanced Sinonasal Carcinoma
Not reviewed·Conditions: Sinonasal Undifferentiated Carcinoma·Matched via name phrase
- NCT06940180·RECRUITING·Toripalimab With Chemotherapy for Sinus Cancer
Not reviewed·Conditions: Sinonasal Cancer · Paranasal Sinus Neoplasms · Squamous Cell Carcinoma · Sinonasal Undifferentiated Carcinoma·Matched via name phrase
- NCT06814496·RECRUITING·Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Not reviewed·Conditions: Melanoma · Medullary Thyroid Cancer · Sinonasal Undifferentiated Carcinoma · Esthesioneuroblastoma·Matched via name phrase
- NCT06176989·RECRUITING·Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Not reviewed·Conditions: Metastatic Chondrosarcoma · Locally Advanced Chondrosarcoma · Metastatic Sinonasal Adenocarcinoma · Locally Advanced Sinonasal Adenocarcinoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 3 · after dedupe 3 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 3 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (3)
- isrctn·ISRCTN11659025·No longer recruiting·PORTEC-4a: Randomised trial of standard or molecular profile-based recommendation for radiotherapy after surgery for women with early stage endometrial cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN43261139·No longer recruiting·Study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN59521990·No longer recruiting·A randomised controlled trial of colorectal polyp and cancer prevention using aspirin and resistant starch in carriers of hereditary nonpolyposis colorectal cancer
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Undifferentiated carcinoma of the corpus uteri — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Undifferentiated carcinoma of the corpus uteri" OR "Undifferentiated carcinoma of corpus uteri" OR "Endometrial undifferentiated carcinoma" OR "body of uterus undifferentiated carcinoma" OR "body of the uterus undifferentiated carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Undifferentiated carcinoma of the corpus uteri" OR "Undifferentiated carcinoma of corpus uteri" OR "Endometrial undifferentiated carcinoma" OR "body of uterus undifferentiated carcinoma" OR "body of the uterus undifferentiated carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 17 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"undifferentiated carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:36:37.865Z